25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Vaccibody AS
Buy, Hold or Sell?

Let's analyze Vaccibody AS together

I guess you are interested in Vaccibody AS. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vaccibody AS. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Vaccibody AS

I send you an email if I find something interesting about Vaccibody AS.

1. Quick Overview

1.1. Quick analysis of Vaccibody AS (30 sec.)










1.2. What can you expect buying and holding a share of Vaccibody AS? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.44
Expected worth in 1 year
€0.44
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
€-0.01
Return On Investment
-2.8%

For what price can you sell your share?

Current Price per Share
€0.24
Expected price per share
€0.1739 - €0.4186
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Vaccibody AS (5 min.)




Live pricePrice per Share (EOD)
€0.24

2.2. Growth of Vaccibody AS (5 min.)




Is Vaccibody AS growing?

Current yearPrevious yearGrowGrow %
How rich?$152m$153m$65.5k0.0%

How much money is Vaccibody AS making?

Current yearPrevious yearGrowGrow %
Making money-$9.4m-$11.6m$2.1m23.1%
Net Profit Margin-950.3%-816.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Vaccibody AS (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Vaccibody AS?

Welcome investor! Vaccibody AS's management wants to use your money to grow the business. In return you get a share of Vaccibody AS.

First you should know what it really means to hold a share of Vaccibody AS. And how you can make/lose money.

Speculation

The Price per Share of Vaccibody AS is €0.24. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vaccibody AS.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vaccibody AS, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.44. Based on the TTM, the Book Value Change Per Share is €0.00 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vaccibody AS.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.02-9.4%-0.03-12.4%-0.04-16.6%-0.03-11.1%-0.03-11.1%
Usd Book Value Change Per Share-0.02-8.5%0.00-0.7%-0.04-15.8%0.0416.2%0.0416.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-8.5%0.00-0.7%-0.04-15.8%0.0416.2%0.0416.2%
Usd Price Per Share1.35-1.71-2.39-3.30-3.30-
Price to Earnings Ratio-14.95--16.88--15.42--17.92--17.92-
Price-to-Total Gains Ratio-66.51--37.20--64.90--57.39--57.39-
Price to Book Ratio2.90-3.59-4.60-5.82-5.82-
Price-to-Total Gains Ratio-66.51--37.20--64.90--57.39--57.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.251496
Number of shares3976
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.04
Usd Total Gains Per Share0.000.04
Gains per Quarter (3976 shares)-7.02154.31
Gains per Year (3976 shares)-28.07617.24
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-28-380617607
20-56-66012341224
30-84-94018521841
40-112-122024692458
50-140-150030863075
60-168-178037033692
70-197-206043214309
80-225-234049384926
90-253-262055555543
100-281-290061726160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.011.00.08.3%1.011.00.08.3%1.011.00.08.3%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%3.09.00.025.0%3.09.00.025.0%3.09.00.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%3.09.00.025.0%3.09.00.025.0%3.09.00.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Vaccibody AS compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.019-0.002-91%-0.036+86%0.037-152%0.037-152%
Book Value Per Share--0.4440.457-3%0.497-11%0.518-14%0.518-14%
Current Ratio--9.2808.173+14%6.077+53%8.328+11%8.328+11%
Debt To Asset Ratio--0.1550.189-18%0.274-44%0.235-34%0.235-34%
Debt To Equity Ratio--0.1830.237-23%0.378-52%0.312-41%0.312-41%
Dividend Per Share----0%-0%-0%-0%
Eps---0.022-0.028+32%-0.038+76%-0.026+18%-0.026+18%
Free Cash Flow Per Share---0.038-0.066+71%-0.046+20%-0.034-11%-0.034-11%
Free Cash Flow To Equity Per Share---0.038-0.066+71%-0.046+20%-0.034-11%-0.034-11%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap--421571459.204516073508.071-18%671349057.111-37%929849900.809-55%929849900.809-55%
Net Profit Margin---13.581-9.503-30%-8.168-40%-7.519-45%-7.519-45%
Operating Margin----0%-0%-0%-0%
Operating Ratio--22.66714.557+56%12.010+89%11.288+101%11.288+101%
Pb Ratio0.540-438%2.9053.591-19%4.602-37%5.823-50%5.823-50%
Pe Ratio-2.779+81%-14.949-16.877+13%-15.421+3%-17.922+20%-17.922+20%
Price Per Share0.240-438%1.2911.631-21%2.285-43%3.153-59%3.153-59%
Price To Free Cash Flow Ratio-1.563+81%-8.410-7.791-7%-14.325+70%-10.249+22%-10.249+22%
Price To Total Gains Ratio-12.364+81%-66.510-37.199-44%-64.896-2%-57.389-14%-57.389-14%
Quick Ratio---0.009-100%0.034-100%0.342-100%0.342-100%
Return On Assets---0.041-0.051+24%-0.055+34%-0.040-2%-0.040-2%
Return On Equity---0.049-0.063+30%-0.076+56%-0.053+8%-0.053+8%
Total Gains Per Share---0.019-0.002-91%-0.036+86%0.037-152%0.037-152%
Usd Book Value--152079668.296153090429.384-1%153024928.665-1%162535199.658-6%162535199.658-6%
Usd Book Value Change Per Share---0.020-0.002-91%-0.038+86%0.039-152%0.039-152%
Usd Book Value Per Share--0.4660.479-3%0.521-11%0.543-14%0.543-14%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.023-0.030+32%-0.040+76%-0.027+18%-0.027+18%
Usd Free Cash Flow---13132144.058-22113492.582+68%-14221406.007+8%-11220789.757-15%-11220789.757-15%
Usd Free Cash Flow Per Share---0.040-0.069+71%-0.048+20%-0.036-11%-0.036-11%
Usd Free Cash Flow To Equity Per Share---0.040-0.069+71%-0.048+20%-0.036-11%-0.036-11%
Usd Market Cap--441764732.100540793429.107-18%703506676.946-37%974389711.058-55%974389711.058-55%
Usd Price Per Share0.251-438%1.3531.709-21%2.394-43%3.304-59%3.304-59%
Usd Profit---7388081.046-9478603.979+28%-11666877.984+58%-8075588.588+9%-8075588.588+9%
Usd Revenue--544005.9681536766.858-65%2866031.440-81%4445798.770-88%4445798.770-88%
Usd Total Gains Per Share---0.020-0.002-91%-0.038+86%0.039-152%0.039-152%
 EOD+3 -3MRQTTM+16 -16YOY+19 -135Y+9 -2310Y+9 -23

3.3 Fundamental Score

Let's check the fundamental score of Vaccibody AS based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.779
Price to Book Ratio (EOD)Between0-10.540
Net Profit Margin (MRQ)Greater than0-13.581
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than19.280
Debt to Asset Ratio (MRQ)Less than10.155
Debt to Equity Ratio (MRQ)Less than10.183
Return on Equity (MRQ)Greater than0.15-0.049
Return on Assets (MRQ)Greater than0.05-0.041
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Vaccibody AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.103
Ma 20Greater thanMa 500.305
Ma 50Greater thanMa 1000.384
Ma 100Greater thanMa 2000.654
OpenGreater thanClose0.240
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Vaccibody AS

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Vaccibody AS earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Vaccibody AS to the  industry mean.
  • A Net Profit Margin of -1,358.1% means that €-13.58 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vaccibody AS:

  • The MRQ is -1,358.1%. The company is making a huge loss. -2
  • The TTM is -950.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,358.1%TTM-950.3%-407.8%
TTM-950.3%YOY-816.8%-133.5%
TTM-950.3%5Y-751.9%-198.3%
5Y-751.9%10Y-751.9%0.0%
4.3.1.2. Return on Assets

Shows how efficient Vaccibody AS is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vaccibody AS to the  industry mean.
  • -4.1% Return on Assets means that Vaccibody AS generated €-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vaccibody AS:

  • The MRQ is -4.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.1%TTM-5.1%+1.0%
TTM-5.1%YOY-5.5%+0.4%
TTM-5.1%5Y-4.0%-1.1%
5Y-4.0%10Y-4.0%0.0%
4.3.1.3. Return on Equity

Shows how efficient Vaccibody AS is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vaccibody AS to the  industry mean.
  • -4.9% Return on Equity means Vaccibody AS generated €-0.05 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vaccibody AS:

  • The MRQ is -4.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.9%TTM-6.3%+1.5%
TTM-6.3%YOY-7.6%+1.3%
TTM-6.3%5Y-5.3%-1.1%
5Y-5.3%10Y-5.3%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Vaccibody AS.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Vaccibody AS is operating .

  • Measures how much profit Vaccibody AS makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vaccibody AS to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vaccibody AS:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Vaccibody AS is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 22.67 means that the operating costs are €22.67 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Vaccibody AS:

  • The MRQ is 22.667. The company is inefficient in keeping operating costs low. -1
  • The TTM is 14.557. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ22.667TTM14.557+8.111
TTM14.557YOY12.010+2.547
TTM14.5575Y11.288+3.269
5Y11.28810Y11.2880.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Vaccibody AS.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Vaccibody AS is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 9.28 means the company has €9.28 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Vaccibody AS:

  • The MRQ is 9.280. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.173. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.280TTM8.173+1.107
TTM8.173YOY6.077+2.096
TTM8.1735Y8.328-0.155
5Y8.32810Y8.3280.000
4.4.3.2. Quick Ratio

Measures if Vaccibody AS is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vaccibody AS to the  industry mean.
  • A Quick Ratio of 0.00 means the company can pay off €0.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vaccibody AS:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.009-0.009
TTM0.009YOY0.034-0.026
TTM0.0095Y0.342-0.333
5Y0.34210Y0.3420.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Vaccibody AS.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Vaccibody AS assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vaccibody AS to industry mean.
  • A Debt to Asset Ratio of 0.15 means that Vaccibody AS assets are financed with 15.5% credit (debt) and the remaining percentage (100% - 15.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vaccibody AS:

  • The MRQ is 0.155. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.189. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.155TTM0.189-0.035
TTM0.189YOY0.274-0.085
TTM0.1895Y0.235-0.046
5Y0.23510Y0.2350.000
4.5.4.2. Debt to Equity Ratio

Measures if Vaccibody AS is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vaccibody AS to the  industry mean.
  • A Debt to Equity ratio of 18.3% means that company has €0.18 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vaccibody AS:

  • The MRQ is 0.183. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.237. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.183TTM0.237-0.054
TTM0.237YOY0.378-0.142
TTM0.2375Y0.312-0.075
5Y0.31210Y0.3120.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Vaccibody AS generates.

  • Above 15 is considered overpriced but always compare Vaccibody AS to the  industry mean.
  • A PE ratio of -14.95 means the investor is paying €-14.95 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vaccibody AS:

  • The EOD is -2.779. Based on the earnings, the company is expensive. -2
  • The MRQ is -14.949. Based on the earnings, the company is expensive. -2
  • The TTM is -16.877. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.779MRQ-14.949+12.170
MRQ-14.949TTM-16.877+1.928
TTM-16.877YOY-15.421-1.456
TTM-16.8775Y-17.922+1.046
5Y-17.92210Y-17.9220.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vaccibody AS:

  • The EOD is -1.563. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.410. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.791. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.563MRQ-8.410+6.847
MRQ-8.410TTM-7.791-0.619
TTM-7.791YOY-14.325+6.534
TTM-7.7915Y-10.249+2.458
5Y-10.24910Y-10.2490.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Vaccibody AS is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 2.90 means the investor is paying €2.90 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Vaccibody AS:

  • The EOD is 0.540. Based on the equity, the company is cheap. +2
  • The MRQ is 2.905. Based on the equity, the company is underpriced. +1
  • The TTM is 3.591. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD0.540MRQ2.905-2.365
MRQ2.905TTM3.591-0.686
TTM3.591YOY4.602-1.011
TTM3.5915Y5.823-2.232
5Y5.82310Y5.8230.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets179,877
Total Liabilities27,799
Total Stockholder Equity152,078
 As reported
Total Liabilities 27,799
Total Stockholder Equity+ 152,078
Total Assets = 179,877

Assets

Total Assets179,877
Total Current Assets140,020
Long-term Assets39,857
Total Current Assets
Cash And Cash Equivalents 136,534
Total Current Assets  (as reported)140,020
Total Current Assets  (calculated)136,534
+/- 3,486
Long-term Assets
Property Plant Equipment 9,284
Long-term Assets  (as reported)39,857
Long-term Assets  (calculated)9,284
+/- 30,573

Liabilities & Shareholders' Equity

Total Current Liabilities15,089
Long-term Liabilities12,710
Total Stockholder Equity152,078
Total Current Liabilities
Accounts payable 3,417
Total Current Liabilities  (as reported)15,089
Total Current Liabilities  (calculated)3,417
+/- 11,672
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,786
Long-term Liabilities Other 877
Long-term Liabilities  (as reported)12,710
Long-term Liabilities  (calculated)5,663
+/- 7,047
Total Stockholder Equity
Retained Earnings 7,726
Total Stockholder Equity (as reported)152,078
Total Stockholder Equity (calculated)7,726
+/- 144,352
Other
Capital Stock367
Common Stock Shares Outstanding 326,546
Net Invested Capital 152,078
Net Working Capital 124,931
Property Plant and Equipment Gross 9,284



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
202,650
265,556
254,073
238,832
228,314
221,477
205,272
188,839
174,470
208,185
191,891
179,877
179,877191,891208,185174,470188,839205,272221,477228,314238,832254,073265,556202,650
   > Total Current Assets 
201,734
255,858
244,076
228,875
218,619
211,873
195,160
177,822
163,361
165,675
151,832
140,020
140,020151,832165,675163,361177,822195,160211,873218,619228,875244,076255,858201,734
       Cash And Cash Equivalents 
172,645
215,759
225,681
213,279
212,021
205,843
186,163
173,583
159,132
161,954
147,296
136,534
136,534147,296161,954159,132173,583186,163205,843212,021213,279225,681215,759172,645
       Short-term Investments 
16,319
12,169
12,234
10,035
0
0
0
0
0
0
0
0
0000000010,03512,23412,16916,319
       Net Receivables 
3,750
23,750
2,500
2,689
2,544
2,544
11
11
542
0
220
0
0220054211112,5442,5442,6892,50023,7503,750
   > Long-term Assets 
917
9,698
9,997
9,957
9,695
9,604
10,112
11,017
11,109
42,510
40,059
39,857
39,85740,05942,51011,10911,01710,1129,6049,6959,9579,9979,698917
       Property Plant Equipment 
0
0
0
0
9,214
9,526
10,036
10,901
11,037
10,517
9,928
9,284
9,2849,92810,51711,03710,90110,0369,5269,2140000
       Intangible Assets 
0
32
0
0
0
32
0
0
0
0
0
0
00000032000320
> Total Liabilities 
40,475
71,501
65,432
57,750
61,203
64,458
57,012
49,136
44,172
36,926
33,171
27,799
27,79933,17136,92644,17249,13657,01264,45861,20357,75065,43271,50140,475
   > Total Current Liabilities 
10,923
31,367
31,129
27,026
35,566
38,985
33,139
26,006
23,517
20,608
18,019
15,089
15,08918,01920,60823,51726,00633,13938,98535,56627,02631,12931,36710,923
       Accounts payable 
7,037
2,746
6,985
5,394
5,274
2,313
7,293
7,046
7,001
1,327
3,993
3,417
3,4173,9931,3277,0017,0467,2932,3135,2745,3946,9852,7467,037
       Other Current Liabilities 
1
0
0
-1
1
0
0
-1
0
0
0
0
0000-1001-1001
   > Long-term Liabilities 
29,552
40,134
34,303
30,724
25,637
25,473
23,873
23,130
20,655
16,318
15,152
12,710
12,71015,15216,31820,65523,13023,87325,47325,63730,72434,30340,13429,552
       Capital Lease Obligations Min Short Term Debt
65
7,170
6,989
5,993
5,171
5,512
5,503
6,078
5,797
5,726
5,131
4,786
4,7865,1315,7265,7976,0785,5035,5125,1715,9936,9897,17065
> Total Stockholder Equity
162,175
194,055
188,641
181,082
167,111
157,019
148,260
139,703
130,298
171,259
158,720
152,078
152,078158,720171,259130,298139,703148,260157,019167,111181,082188,641194,055162,175
   Common Stock000000000000
   Retained Earnings 
96,686
107,455
100,557
91,808
76,918
64,713
54,351
45,140
34,897
29,559
15,115
7,726
7,72615,11529,55934,89745,14054,35164,71376,91891,808100,557107,45596,686
   Capital Surplus 000000000000
   Treasury Stock000000000000
   Other Stockholders Equity 000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue12,902
Cost of Revenue--
Gross Profit-12,902
 
Operating Income (+$)
Gross Profit-
Operating Expense-70,984
Operating Income-58,082-70,984
 
Operating Expense (+$)
Research Development29,358
Selling General Administrative6,278
Selling And Marketing Expenses-
Operating Expense70,98435,636
 
Net Interest Income (+$)
Interest Income8,946
Interest Expense-224
Other Finance Cost-0
Net Interest Income8,722
 
Pretax Income (+$)
Operating Income-58,082
Net Interest Income8,722
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-44,086-58,082
EBIT - interestExpense = -224
-35,154
-34,930
Interest Expense224
Earnings Before Interest and Taxes (EBIT)--43,862
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-44,086
Tax Provision--8,932
Net Income From Continuing Ops-35,154-35,154
Net Income-35,154
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--8,722
 

Technical Analysis of Vaccibody AS
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vaccibody AS. The general trend of Vaccibody AS is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vaccibody AS's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vaccibody AS.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.4186 < 0.4186 < 0.4186.

The bearish price targets are: 0.1739 > 0.1739 > 0.1739.

Tweet this
Vaccibody AS Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vaccibody AS. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vaccibody AS Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vaccibody AS. The current macd is -0.06134873.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vaccibody AS price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vaccibody AS. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vaccibody AS price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Vaccibody AS Daily Moving Average Convergence/Divergence (MACD) ChartVaccibody AS Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vaccibody AS. The current adx is 81.61.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vaccibody AS shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Vaccibody AS Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vaccibody AS. The current sar is 0.34460409.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vaccibody AS Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vaccibody AS. The current rsi is 30.10. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Vaccibody AS Daily Relative Strength Index (RSI) ChartVaccibody AS Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vaccibody AS. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vaccibody AS price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Vaccibody AS Daily Stochastic Oscillator ChartVaccibody AS Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vaccibody AS. The current cci is -40.00321925.

Vaccibody AS Daily Commodity Channel Index (CCI) ChartVaccibody AS Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vaccibody AS. The current cmo is -23.75837066.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vaccibody AS Daily Chande Momentum Oscillator (CMO) ChartVaccibody AS Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vaccibody AS. The current willr is -73.22802754.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vaccibody AS is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Vaccibody AS Daily Williams %R ChartVaccibody AS Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vaccibody AS.

Vaccibody AS Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vaccibody AS. The current atr is 0.01366849.

Vaccibody AS Daily Average True Range (ATR) ChartVaccibody AS Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vaccibody AS. The current obv is -129,430.

Vaccibody AS Daily On-Balance Volume (OBV) ChartVaccibody AS Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vaccibody AS. The current mfi is 2.40400668.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Vaccibody AS Daily Money Flow Index (MFI) ChartVaccibody AS Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vaccibody AS.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-10MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-25ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Vaccibody AS Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vaccibody AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.103
Ma 20Greater thanMa 500.305
Ma 50Greater thanMa 1000.384
Ma 100Greater thanMa 2000.654
OpenGreater thanClose0.240
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Vaccibody AS with someone you think should read this too:
  • Are you bullish or bearish on Vaccibody AS? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vaccibody AS? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vaccibody AS

I send you an email if I find something interesting about Vaccibody AS.


Comments

How you think about this?

Leave a comment

Stay informed about Vaccibody AS.

Receive notifications about Vaccibody AS in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.